Literature DB >> 31513254

Lack of Robust Prognostic Biomarkers for Immunotherapy in Breast Cancer-Adverse Events-In Reply.

Sylvia Adams1, Elizabeth A Mittendorf2,3.   

Abstract

Year:  2019        PMID： 31513254     DOI： 10.1001/jamaoncol.2019.3605

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  5 in total

Review 1.  Breast cancer vaccines for treatment and prevention.

Authors:  Mary L Disis; Denise L Cecil
Journal:  Breast Cancer Res Treat       Date:  2021-11-30       Impact factor: 4.872

2.  Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis.

Authors:  Nadia Bianco; Monica Milano; Eleonora Pagan; Chiara Oriecuia; Vincenzo Bagnardi; Elena Guerini Rocco; Giorgia Irene Santomauro; Giulia Peruzzotti; Marco Colleoni; Giuseppe Viale
Journal:  Breast Cancer Res Treat       Date:  2021-10-05       Impact factor: 4.872

Review 3.  Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.

Authors:  Molly A Nelson; Worapol Ngamcherdtrakul; Shiuh-Wen Luoh; Wassana Yantasee
Journal:  Cancer Metastasis Rev       Date:  2021-05-07       Impact factor: 9.237

Review 4.  Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy.

Authors:  Jia Wu; Aaron T Mayer; Ruijiang Li
Journal:  Semin Cancer Biol       Date:  2020-12-05       Impact factor: 17.012

Review 5.  Immune-related biomarkers in triple-negative breast cancer.

Authors:  Juan Zhang; Qi Tian; Mi Zhang; Hui Wang; Lei Wu; Jin Yang
Journal:  Breast Cancer       Date:  2021-04-09       Impact factor: 4.239
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.